Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Bonetti

Showing results (21-30 of 132) with videos related to

Pageof 14
Sort By:
Journal of Gastrointestinal Cancer|September 5, 2015
The Occurrence of Gastrointestinal Stromal Tumors and Second MalignanciesJacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer|December 25, 2015
Second-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung CancerJacopo Giuliani, Andrea Bonetti
Clinical Genitourinary Cancer|March 15, 2018
Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell CarcinomaJacopo Giuliani, Andrea Bonetti
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 5, 2017
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian CancerJacopo Giuliani, Andrea Bonetti
European Journal of Cancer (Oxford, England : 1990)|September 2, 2020
Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costsJacopo Giuliani, Andrea Bonetti
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
History of intraperitoneal platinum drug delivery for ovarian cancer and its future applicationsFranco Muggia, Andrea Bonetti
Oral Oncology|August 22, 2019
Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) levelJacopo Giuliani, Andrea Bonetti
Current Opinion in Oncology|June 17, 2020
Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world dataJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|April 12, 2017
Elderly patients with advanced pancreatic cancer: the generalizability of the results of clinical trials to daily clinical practiceJacopo Giuliani, Andrea Bonetti
Expert Review of Pharmacoeconomics & Outcomes Research|August 6, 2019
Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatmentJacopo Giuliani, Andrea Bonetti
Pageof 14

Showing results (21-30 of 132) with videos related to

Sort By:
Pageof 14
Journal of Gastrointestinal Cancer|September 5, 2015
The Occurrence of Gastrointestinal Stromal Tumors and Second MalignanciesJacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer|December 25, 2015
Second-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung CancerJacopo Giuliani, Andrea Bonetti
Clinical Genitourinary Cancer|March 15, 2018
Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell CarcinomaJacopo Giuliani, Andrea Bonetti
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 5, 2017
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian CancerJacopo Giuliani, Andrea Bonetti
European Journal of Cancer (Oxford, England : 1990)|September 2, 2020
Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costsJacopo Giuliani, Andrea Bonetti
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
History of intraperitoneal platinum drug delivery for ovarian cancer and its future applicationsFranco Muggia, Andrea Bonetti
Oral Oncology|August 22, 2019
Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) levelJacopo Giuliani, Andrea Bonetti
Current Opinion in Oncology|June 17, 2020
Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world dataJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|April 12, 2017
Elderly patients with advanced pancreatic cancer: the generalizability of the results of clinical trials to daily clinical practiceJacopo Giuliani, Andrea Bonetti
Expert Review of Pharmacoeconomics & Outcomes Research|August 6, 2019
Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatmentJacopo Giuliani, Andrea Bonetti
Pageof 14